Clinical Trial

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2024 (before its estimated August 16, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, phase II clinical study aim to evaluate the efficacy and safety of long-term concurrent chemoradiotherapy combined with camrelizumab as a neoadjuvant therapy in the treatment of locally advanced/low rectal cancer requiring anus preservation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-05.
Trial Details
NCT Number NCT06304545
Lead Sponsor Harbin Medical University
Conditions Rectal Cancer
Enrollment 48 participants
Start Date 2024-03-15
Primary Completion 2026-08-16 (estimated)
Study Completion 2027-03-15 (estimated)
Updated on ClinicalTrials.gov 2024-03-12